Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition for treating withdrawal syndrome

A composition and syndrome technology, applied in the field of indole derivatives or their salts, can solve the problems of general effect of treating withdrawal syndrome and the like, and achieve the effects of no adverse reactions, low toxicity and convenient medication

Inactive Publication Date: 2011-09-28
INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the overall effect of melotonin in the treatment of withdrawal syndrome is mediocre, and it requires intraperitoneal injection. At present, there is no literature report on the clinical use of this type of preparation in the treatment of withdrawal syndrome.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating withdrawal syndrome
  • Pharmaceutical composition for treating withdrawal syndrome
  • Pharmaceutical composition for treating withdrawal syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: Synthesis of 2-bromo-N-acetyl-5-methoxytryptamine

[0023] N-bromosuccinimide (NBS, 0.89g, 5mM) was slowly added to anhydrous acetic acid solution of melatonin (1.16g, 5mM) under stirring, stirred at room temperature for 3 hours under nitrogen, and ice water Cool and neutralize to neutral with 50% sodium hydroxide to obtain an oily suspension product. After the aqueous phase was extracted four times with chloroform, the organic phases were combined, treated with saturated sodium chloride solution, and then dried by adding anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to obtain a tan oily crude product. The crude product was subjected to column chromatography on a silica gel column (mobile phase: ethyl acetate-cyclohexane=8:2) to obtain the product, which was recrystallized from ethyl acetate-cyclohexane solution to obtain the product, mp: 145-149°C.

Embodiment 2

[0024] Embodiment two: acute toxicity test

[0025] 1 Acute toxicity test in mice

[0026] The Experimental Animal Center of the Academy of Military Medical Sciences produced Kunming mice, 35-40 days old, half male and half female, female mice weighing 19.8±0.7g, and male mice weighing 21.0±0.6g. Administration method: The route of administration is intragastric administration. The experimental animals were fasted for 12 hours, and the test drugs were administered once by intragastric administration according to the same volume and different administration concentrations, and the volume was 0.5ml / animal.

[0027] After the drug, the animal moved lazily, did not eat, and became drunk after 20 minutes, and then lay still in the cage until death or recovery. The higher the dose, the more obvious it is. Surviving animals returned to normal within 1-3 days after administration.

[0028] Mice were fed with 2-bromo-N-acetyl-5-methoxytryptamine once, and the LD50 of female animals...

Embodiment 3

[0033] Example 3: Therapeutic effect on urging withdrawal symptoms in morphine-dependent mice

[0034] Kunming mice were bred by the Experimental Animal Center of the Academy of Military Medical Sciences, Grade II. Male and female are half and half, body weight is 20±2g. Morphine hydrochloride injection (manufactured by Shenyang No. 1 Pharmaceutical Factory, batch number: 040102, specification: 1ml: 10mg), naloxone hydrochloride injection (produced by Beijing Sihuan Pharmaceutical Technology Co., Ltd., batch number: 0403251, specification: 1ml: 0.4mg ), 2-bromo-N-acetyl-5-methoxytryptamine, synthesized by the Medicinal Chemistry Laboratory, Institute of Radiation and Radiation Medicine, Academy of Military Medical Sciences. Experimental equipment includes syringes, beakers, balances, gavage devices, timers and counters.

[0035] The experiment was divided into model control group, 2-bromo-N-acetyl-5-methoxytryptamine low-dose 2.5mg / kg group, middle-dose 5mg / kg group and high...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating abstinence syndrome of opium substances which comprises medicinal carrying agent, and the active composition being indole derivative or salts. The medicinal composition has the advantages of low toxicity, appreciable curative effect, non-addiction, and easy administration.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating withdrawal syndrome, in particular, an indole derivative or a salt thereof for treating opioid withdrawal syndrome. Background technique [0002] The abuse of opioids can cause serious addiction, and once the drug is stopped, painful and abnormal withdrawal symptoms will appear, which will cause great damage to the body. The public health and social problems caused by taking such drugs have become increasingly prominent, and drug use and the social problems caused by drug use have become a cancer in today's international society. Therefore, it is the direction that people have been working hard to explore measures and methods to prevent and treat opioid dependence and withdrawal syndrome. [0003] At present, there are two main categories of therapeutic drugs, one is alternative drugs with opioid receptors as the main target, and the other is non-alternative drugs. The former is mainl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/404A61P25/36
Inventor 吕秋军黄荣清任建平骆传环肖炳坤陈媛媛温利青卞广兴张敏
Owner INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA